BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum 2019;49:74-83. [PMID: 30598332 DOI: 10.1016/j.semarthrit.2018.11.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 McFarlane PA, Bitzan M, Broome C, Baran D, Garland J, Girard LP, Grewal K, Lapeyraque AL, Patriquin CJ, Pavenski K, Licht C. Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review. Can J Kidney Health Dis 2021;8:20543581211008707. [PMID: 33996107 DOI: 10.1177/20543581211008707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
3 Hiepe F. Neue Erkenntnisse zur Pathogenese des SLE und ihre Auswirkungen auf die Entwicklung neuer Therapie-Konzepte. Aktuelle Rheumatologie 2020;45:328-33. [DOI: 10.1055/a-1210-2259] [Reference Citation Analysis]
4 Ruffatti A, Tonello M, Macor P, Calligaro A, Del Ross T, Favaro M, Lotti V, Carletto A, Hoxha A, Biasi D. Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome. Blood 2021;137:2989-92. [PMID: 33649771 DOI: 10.1182/blood.2020010575] [Reference Citation Analysis]
5 Gkrouzman E, Smith MH, Ghosh N, Laurence JC, Seshan SV, Vaughn JL, Levine AB, Bass AR, Erkan D. Recurrent Complement-Mediated Thrombotic Microangiopathy in a Patient with Systemic Lupus Erythematosus: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery. HSS J 2020;16:507-14. [PMID: 33380989 DOI: 10.1007/s11420-020-09761-9] [Reference Citation Analysis]
6 Blasco M, Guillén E, Quintana LF, Garcia-Herrera A, Piñeiro G, Poch E, Carreras E, Campistol JM, Diaz-Ricart M, Palomo M. Thrombotic microangiopathies assessment: mind the complement. Clin Kidney J 2021;14:1055-66. [PMID: 33841853 DOI: 10.1093/ckj/sfaa195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Maria NI, Davidson A. Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nat Rev Rheumatol 2020;16:255-67. [PMID: 32203285 DOI: 10.1038/s41584-020-0401-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
8 Erton ZB, Erkan D. Treatment advances in antiphospholipid syndrome: 2022 update. Current Opinion in Pharmacology 2022;65:102212. [DOI: 10.1016/j.coph.2022.102212] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cervera R, Rodríguez-pintó I, Legault K, Erkan D. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Lupus 2020;29:1594-600. [DOI: 10.1177/0961203320951260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mejia-Vilet JM, Gómez-Ruiz IA, Cruz C, Méndez-Pérez RA, Comunidad-Bonilla RA, Uribe-Uribe NO, Nuñez-Alvarez CA, Morales-Buenrostro LE. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis. Clin Rheumatol 2021;40:2233-42. [PMID: 33170371 DOI: 10.1007/s10067-020-05499-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Vitkauskaitė M, Vinikovas A, Miglinas M, Rimševičius L, Čerkauskaitė A, Mačionienė E, Ašakienė E. Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5573] [Reference Citation Analysis]
12 Davidson A, Aranow C, Mackay M. Lupus nephritis: challenges and progress. Curr Opin Rheumatol 2019;31:682-8. [PMID: 31389814 DOI: 10.1097/BOR.0000000000000642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Mahroum N, Zoubi M, Lavine N, Ohayon A, Amital H, Shoenfeld Y. The mosaic of autoimmunity - A taste for more. The 12th international congress of autoimmunity 2021 (AUTO12) virtual. Autoimmun Rev 2021;20:102945. [PMID: 34509655 DOI: 10.1016/j.autrev.2021.102945] [Reference Citation Analysis]
14 Erkan D. Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome. Arthritis Rheumatol 2021. [PMID: 34114366 DOI: 10.1002/art.41891] [Reference Citation Analysis]
15 Xiao H, Wu K, Liang X, Li R, Lai KP. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis. Front Immunol 2021;12:715036. [PMID: 34456922 DOI: 10.3389/fimmu.2021.715036] [Reference Citation Analysis]
16 Galindo-Izquierdo M, Pablos Alvarez JL. Complement as a Therapeutic Target in Systemic Autoimmune Diseases. Cells 2021;10:148. [PMID: 33451011 DOI: 10.3390/cells10010148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Lee WF, Wu CY, Yang HY, Lee WI, Chen LC, Ou LS, Huang JL. Biomarkers associating endothelial Dysregulation in pediatric-onset systemic lupus erythematous. Pediatr Rheumatol Online J 2019;17:69. [PMID: 31651352 DOI: 10.1186/s12969-019-0369-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
18 Chebbi PP, Goel R, Ramya J, Gowri M, Herrick A, Danda D. Nailfold capillaroscopy changes associated with anti-RNP antibodies in systemic lupus erythematosus. Rheumatol Int 2021. [PMID: 34076720 DOI: 10.1007/s00296-021-04894-4] [Reference Citation Analysis]
19 Ayoub I, Cassol C, Almaani S, Rovin B, Parikh SV. The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future. Adv Chronic Kidney Dis 2019;26:360-8. [PMID: 31733720 DOI: 10.1053/j.ackd.2019.08.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
20 Zhao K, Zhou P, Xu L, Li R, Yang J, Zhang Q, Yang M, Wei X. Was Antiphospholipid Syndrome a Risk Factor of Stroke? A Systemic Review and Meta-Analysis of Cohort Studies. Dis Markers 2021;2021:4431907. [PMID: 34956419 DOI: 10.1155/2021/4431907] [Reference Citation Analysis]
21 Nasonov EL, Beketova TV, Reshetnyak TM, Lila AM, Ananieva LP, Lisitsyna TA, Soloviev SK. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Naučno-praktičeskaâ revmatologiâ 2020;58:353-67. [DOI: 10.47360/1995-4484-2020-353-367] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 7.5] [Reference Citation Analysis]
22 Tinti MG, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A, De Cata A. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med 2019;19:281-8. [PMID: 31214910 DOI: 10.1007/s10238-019-00565-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
23 Estrada CC, Cardona S, Guo Y, Revelo MP, D'Agati VD, Koganti S, Devaraj J, He JC, Heeger PS, Mallipattu SK. Endothelial-specific loss of Krüppel-Like Factor 4 triggers complement-mediated endothelial injury. Kidney Int 2022:S0085-2538(22)00344-1. [PMID: 35483525 DOI: 10.1016/j.kint.2022.03.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Cohen H, Sayar Z, Efthymiou M, Gaspar P, Richards T, Isenberg D. Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. Lancet Haematol 2020;7:e613-23. [PMID: 32735839 DOI: 10.1016/S2352-3026(20)30116-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Radin M, Cecchi I, Rubini E, Foddai SG, Barinotti A, Menegatti E, Roccatello D, Sciascia S. Treatment of antiphospholipid syndrome. Clin Immunol 2020;221:108597. [PMID: 32961331 DOI: 10.1016/j.clim.2020.108597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Ferrer-Oliveras R, Mendoza M, Capote S, Pratcorona L, Esteve-Valverde E, Cabero-Roura L, Alijotas-Reig J. Immunological and physiopathological approach of COVID-19 in pregnancy. Arch Gynecol Obstet 2021;304:39-57. [PMID: 33945026 DOI: 10.1007/s00404-021-06061-3] [Reference Citation Analysis]
27 Sevim E, Willis R, Erkan D. Is there a role for immunosuppression in antiphospholipid syndrome? Hematology Am Soc Hematol Educ Program 2019;2019:426-32. [PMID: 31808842 DOI: 10.1182/hematology.2019000073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
28 Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol 2020;21:245. [PMID: 32605540 DOI: 10.1186/s12882-020-01888-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
29 Duineveld C, Wetzels JFM. Complement inhibitors are not useful in secondary hemolytic uremic syndromes. Kidney Int 2019;96:829-33. [PMID: 31543154 DOI: 10.1016/j.kint.2019.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Tseng MH, Fan WL, Liu H, Yang CY, Ding JJ, Lee HJ, Huang SM, Lin SH, Huang JL. Complement Factor I Mutation May Contribute to Development of Thrombotic Microangiopathy in Lupus Nephritis. Front Med (Lausanne) 2020;7:621609. [PMID: 33614676 DOI: 10.3389/fmed.2020.621609] [Reference Citation Analysis]
31 Tannous T, Rosso C, Iannuccilli J, Tannous K, Keating M. Primary Refractory Catastrophic Antiphospholipid Syndrome Masquerading as Buerger's Disease. Cureus 2021;13:e14350. [PMID: 33972907 DOI: 10.7759/cureus.14350] [Reference Citation Analysis]
32 Kotzen ES, Roy S, Jain K. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Adv Chronic Kidney Dis 2019;26:376-86. [PMID: 31733722 DOI: 10.1053/j.ackd.2019.08.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
33 Mitrovic S, Hertig A, Fautrel B. Reply to the Letter: 'Thrombotic microangiopathy in adult-onset Still's disease: the story is just beginning'. Expert Rev Clin Immunol 2019;15:1125-6. [PMID: 31623457 DOI: 10.1080/1744666X.2019.1682893] [Reference Citation Analysis]
34 Miyamae T, Kawabe T. Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome. J Clin Med 2021;10:1240. [PMID: 33802787 DOI: 10.3390/jcm10061240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Madison JA, Duarte-García A, Zuo Y, Knight JS. Treatment of thrombotic antiphospholipid syndrome in adults and children. Curr Opin Rheumatol 2020;32:215-27. [PMID: 32187042 DOI: 10.1097/BOR.0000000000000702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 McDonnell T, Wincup C, Buchholz I, Pericleous C, Giles I, Ripoll V, Cohen H, Delcea M, Rahman A. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev 2020;39:100610. [PMID: 31471128 DOI: 10.1016/j.blre.2019.100610] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
37 Lee WF, Fan WL, Tseng MH, Yang HY, Huang JL, Wu CY. Characteristics and genetic analysis of patients suspected with early-onset systemic lupus erythematosus. Pediatr Rheumatol Online J 2022;20:68. [PMID: 35964089 DOI: 10.1186/s12969-022-00722-6] [Reference Citation Analysis]
38 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Martis N, Jamme M, Bagnis-Isnard C, Pouteil-Noble C, Presne C, Vigneau C, Grangé S, Burtey S, Coindre JP, Wynckel A, Hamidou MA, Kanouni T, Azoulay E, Hié M, Chauveau D, Veyradier A, Rondeau E, Coppo P; French Reference Centre for Thrombotic Microangiopathies. Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: Systemic autoimmune disease-associated TMA. Eur J Intern Med 2021:S0953-6205(21)00199-0. [PMID: 34175183 DOI: 10.1016/j.ejim.2021.05.040] [Reference Citation Analysis]
40 Svenungsson E, Antovic A. The antiphospholipid syndrome – often overlooked cause of vascular occlusions? J Intern Med 2020;287:349-72. [DOI: 10.1111/joim.13022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
41 Nasonov EL, Reshetnyak TM, Alekberova ZS. [Thrombotic microangiopathy in rheumatology: a link between thrombosis and autoimmunity]. Ter Arkh 2020;92:4-14. [PMID: 32598770 DOI: 10.26442/00403660.2020.05.000697] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
42 Orbe Jaramillo IA, De Lucas Collantes C, Martínez de Azagra A, Sebastián E. Systemic lupus erythematosus presenting as thrombotic thrombocytopaenic purpura in a child: a diagnostic challenge. BMJ Case Rep 2020;13:e232002. [PMID: 32878846 DOI: 10.1136/bcr-2019-232002] [Reference Citation Analysis]
43 Fernandez-ruiz R, Belmont HM. The role of anti-complement therapy in lupus nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.02.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Kim MJ, Lee H, Kim YH, Jin SY, Kim HJ, Oh D, Jeon JS. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report. BMC Nephrol 2021;22:86. [PMID: 33691638 DOI: 10.1186/s12882-021-02293-2] [Reference Citation Analysis]
45 Iwafuchi Y, Morioka T, Oyama Y, Goto S, Narita I. Complement Factor H Gene Variant in a Patient with Thrombotic Microangiopathy on a Mixed Clinical Background. Case Rep Nephrol 2021;2021:2519918. [PMID: 34733563 DOI: 10.1155/2021/2519918] [Reference Citation Analysis]
46 Minoia F, Tibaldi J, Muratore V, Gallizzi R, Bracaglia C, Arduini A, Comak E, Vougiouka O, Trauzeddel R, Filocamo G, Mastrangelo A, Micalizzi C, Kasapcopur O, Unsal E, Kitoh T, Tsitsami E, Kostik M, Schmid JP, Prader S, Laube G, Maritsi D, Jelusic M, Shenoi S, Vastert S, Ardissino G, Cron RQ, Ravelli A; MAS/sJIA Working Group of the Pediatric Rheumatology European Society (PReS). Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients. J Pediatr 2021;235:196-202. [PMID: 33836183 DOI: 10.1016/j.jpeds.2021.04.004] [Reference Citation Analysis]
47 Pleguezuelo DE, Díaz-Simón R, Cabrera-Marante O, Lalueza A, Paz-Artal E, Lumbreras C, Serrano Hernández A. Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome. Front Immunol 2021;12:667515. [PMID: 33912194 DOI: 10.3389/fimmu.2021.667515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kim JW, Kim TW, Ryu KH, Park SG, Jeong CY, Park DH. Anaesthetic considerations for patients with antiphospholipid syndrome undergoing non-cardiac surgery. J Int Med Res 2020;48:300060519896889. [PMID: 31937174 DOI: 10.1177/0300060519896889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]